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ABSTRACT
Since its characterization two decades ago, the phosphatase PHOSPHO1 has been the subject of an increasing focus of research. This work
has elucidated PHOSPHO1’s central role in the biomineralization of bone and other hard tissues, but has also implicated the enzyme in
other biological processes in health and disease. During mineralization PHOSPHO1 liberates inorganic phosphate (Pi) to be incorporated
into the mineral phase through hydrolysis of its substrates phosphocholine (PCho) and phosphoethanolamine (PEA). Localization of
PHOSPHO1 within matrix vesicles allows accumulation of Pi within a protected environment where mineral crystals may nucleate and
subsequently invade the organic collagenous scaﬀold. Here, we examine the evidence for this process, ﬁrst discussing the discovery and
characterization of PHOSPHO1, before considering experimental evidence for its canonical role in matrix vesicle–mediated
biomineralization. We also contemplate roles for PHOSPHO1 in disorders of dysregulated mineralization such as vascular calciﬁcation,
along with emerging evidence of its activity in other systems including choline synthesis and homeostasis, and energy metabolism.
© 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
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Introduction
Biomineralization of the skeleton is a fundamental processindispensable for health and wellbeing throughout life. The
vertebrate skeleton is a complex organ that performs varied
and diverse functions encompassing its action as a biomecha-
nical and protective scaﬀold in conjunction with the muscu-
lature, its role in calcium and phosphate ion homeostasis, and
recent evidence demonstrating its capacity as an endocrine
organ involved with energy homeostasis.(1) At the level of
molecular constituents bone is composed of a combination of
inorganic mineral, type I collagen, noncollagenous proteins
(NCPs), and water, arranged into an extremely ordered
hierarchical structure.(2) The ﬁne details of this architecture
remain controversial at the nanostructural level,(3) particularly
with respect to diﬀerences between embryonic and mature
tissue; however, the mineral phase has come to be regarded as
a poorly‐crystalline substituted hydroxyapatite phase, mainly
composed of calcium phosphate.
Biomineralization of the skeleton therefore requires genera-
tion and manipulation of calcium and phosphate ions on a
massive scale. The biological mechanisms through which ions
are liberated, contained, and targeted to the developing
collagenous framework, and ultimately nucleate mineral in a
controlled manner, remain the subject of intense research.
Phosphatase enzymes are essential in promoting biominerali-
zation as one pathway through which inorganic phosphate (Pi)
may be liberated from biological molecules. These include
enzymes with a canonical role in bone development such as
tissue nonspeciﬁc alkaline phosphatase (TNAP). Although TNAP
activity has long been implicated in the mineralization process,
it is now recognized that TNAP is only one component and the
full story requires a more complex biochemical system.
Orphan phosphatase 1 (PHOSPHO1; EC 3.1.3.75; encoded by
the Phospho1 gene in the mouse and the PHOSPHO1 gene in
humans) has been an increasing focus of research in this ﬁeld
over the last 20 years and now holds an established function in
biomineralization. Here we review the scientiﬁc literature on
the characterization, localization, regulation, and activity of
PHOSPHO1 with respect to its role in physiological and
pathological biomineralization, along with potential contribu-
tions to other biological processes.
Characterization, Protein Structure, and
Substrate Speciﬁcity
PHOSPHO1 (originally known as 3X11A) was initially cloned
from chick hypertrophic growth plate chondrocytes, in which a
1 of 12 ◼
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
Received in original form February 22, 2019; revised form April 15, 2019; accepted May 5, 2019. Accepted manuscript online July 7, 2019.
Address correspondence to: Scott Dillon, MSci, The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush,
Midlothian, UK, EH25 9RG. E‐mail: s1542732@sms.ed.ac.uk
JBMR1 Plus (WOA), Vol. 3, No. 7, July 2019, e10202.
DOI: 10.1002/jbm4.10202
© 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
ﬁvefold increase in expression was observed in comparison to
resting or proliferative chondrocytes.(4) This distinct upregula-
tion was also found be approximately 100‐fold higher than in
non‐chondrogenic tissues. Although the speciﬁc function of
this novel protein was at this stage unknown, sequencing of
the 3X11A RNA transcript derived from diﬀerential display
analysis revealed two partially conserved domains that bore
sequence similarity to the phosphotransferase enzyme super-
family, including the ATPases and various phosphatases
catalyzing Pi liberation from a range of phosphomonoester
substrates.(4) Primers designed against these motifs succeeded
in transcribing a 537‐bp fragment from RNA isolated from the
human osteosarcoma SaOS‐2 cell line, demonstrating 69%
similarity to the chicken sequence.(5) These fragments were
identiﬁed as corresponding to several previously unattributed
EST transcripts from both the human and mouse Phospho1
gene, with a high degree of conservation at both the gene and
protein level between these two mammalian species. Chromo-
somal mapping led to the conclusion that the Phospho1 gene
was indeed conserved between the bird and mouse genomes,
located within a region of conserved synteny on the HSA17 and
GGA27 chromosomes, respectively.(5)
Stewart and colleagues(6) used homology modeling to identify
three conserved peptide motifs composing the active site,
certifying PHOSPHO1’s membership of the Mg2+‐dependent
haloacid dehalogenase (HAD) superfamily. These included two
characteristic aspartic acid residues in motif 1 that coordinate the
catalytic Mg2+ ion in this family, along with other markers such as
the hydrophobic amino acid residues within motif 2. Along with
identiﬁcation of orthology between PHOSPHO1 in rat and the
previously identiﬁed species, substantial homology between the
amino acid sequences of PHOSPHO1 and proteins in the fruit ﬂy
was also found, along with several plant species including the
LePS2 phosphatases in the tomato plant involved with phosphate
homeostasis.(7–9)
A PHOSPHO1 model protein structure was developed, based
upon the crystal structure of the phosphoserine phosphatases
(PSPs).(6,10) This model revealed conservation of residues
complexing the substrate phosphate group; however, those
residues that confer substrate speciﬁcity to phosphoserine in the
PSPs are absent. Roberts and colleagues(11) puriﬁed recombinant
human PHOSPHO1 by ampliﬁcation of a curtailed cDNA
transcript from the SaOS‐2 osteosarcoma cell line, and contin-
uous spectrophotometric phosphate assays with several poten-
tial phosphomonoester substrates revealed PHOSPHO1’s speciﬁc
activity toward the metabolites phosphoethanolamine (PEA) and
phosphocholine (PCho), with highest activity between pH 6.0 to
7.2. Disruption of the protein active site using site‐directed
mutagenesis decreased PEA and PCho hydrolysis dramatically to
an undetectable level in some mutants.(12)
Bone Biology and Mineralization
The ubiquitous phosphatase TNAP has a long‐established role
during skeletal biomineralization. Mutations in the ALPL gene are
associated with several skeletal disorders in humans including
various forms of hypophosphatasia.(13–15) Genetic ablation of TNAP
in a mouse model induced a phenotype mimicking infantile
hypophosphatasia with severe skeletal abnormalities,(16,17) in-
cluding those in dental and craniofacial mineralization and
morphology.(18,19) Detailed ultrastructural examination of these
mice revealed that although hypomineralization of the skeleton
was evident, hydroxyapatite mineral crystals were generated as
normal.(20) The hypomineralized phenotype was therefore attrib-
uted to the inability of the mineral phase to propagate in the
absence of TNAP’s hydrolysis of the potent mineralization inhibitor
pyrophosphate (PPi).
(20,21)
These observations led to the hypothesis that another
phosphatase was active during skeletal biomineralization with
PHOSPHO1 a strong candidate to fulﬁll this role. Following the
observation of PHOSPHO1 upregulation in mineralizing hyper-
trophic chondrocytes,(4) immunohistochemistry revealed loca-
lization of the protein to these cells in the chick growth plate,
along with active bone surfaces at the ossiﬁcation front and in
the trabecular compartment.(22) Whole‐mount in situ hybridiza-
tion in the embryonic chick lower limb furthermore demon-
strated expression of PHOSPHO1 restricted to the developing
bones during ossiﬁcation.(23) In vivo suppression of PHOSPHO1
activity using the noncompetitive inhibitor lansoprazole
(identiﬁed speciﬁcally as an inhibitor of PHOSPHO1(24)) during
chick development induced ablation of mineralization in the
lower limb bones.(23) Together these data provided strong
evidence that this novel phosphatase plays a critical role in the
very ﬁrst steps of skeletal biomineralization.
The generation of the PHOSPHO1 knockout mouse
(Phospho1–/–) enabled the detailed investigation of its pheno-
type and thereby allowed interrogation of the enzyme’s
speciﬁc function in the skeleton.(25) Huesa and colleagues(26)
used a variety of compositional and biomechanical analyses to
show that the mineral:matrix ratio of femora of juvenile
Phospho1–/– mice was signiﬁcantly lower than wild‐type
controls, accompanied by plastic deformation upon three‐
point bending and a reduced hardness and elastic modulus. A
further investigation of the mechanical properties of these
bones corroborated this high fracture toughness and also
showed signiﬁcantly higher indentation distance increases
under reference point indentation compared to wild‐type
controls.(27) Histological examination of Phospho1–/– long bones
revealed reduced mineralization in the trabecular compart-
ment, whereas 10% to 15% of 10‐day‐old mice exhibited a
complete lack of secondary ossiﬁcation center development.(25)
These bones also demonstrated osteoid accumulation, a
hallmark of hypophosphatasia (Fig. 1A). Interestingly, micro–
computed tomography (µCT) revealed no diﬀerences between
4‐week‐old Phospho1–/– and wild‐type mice in bone volume
relative to tissue volume (BV/TV), but rather a signiﬁcantly
reduced bone mineral density (BMD) that was accompanied by
diverse spontaneous greenstick fractures and marked thoracic
scoliosis(25) (Fig. 1B). Similarly, PHOSPHO1 plays a critical role in
fracture healing, with induced tibial fractures in Phospho1–/–
mice demonstrating osteoid accumulation and elastic deforma-
tion upon loading at 4 weeks postsurgery.(28)
These ﬁndings have been extended to investigate the
function of PHOSPHO1 in the development of bone’s hydro-
xyapatite mineral phase at the smallest length scales. X‐ray
diﬀraction (XRD) along with thermogravimetric analysis (TGA)
revealed a lower bulk mineral content with signiﬁcantly lower
mineral:matrix ratio in Phospho1–/– femurs, also accompanied
by a smaller apatite crystal size.(29) Backscattered scanning
electron microscopy (BSE‐SEM) furthermore revealed general-
ized hypomineralization relative to wild‐type mice in transverse
tibial cross‐sections of the same animals.(29) Further analysis of
the Phospho1–/– microstructure exposed diﬀuse regions of
hypomineralization in diaphyseal cortical and trabecular bone
with large areas of osteoid accumulation.(30) Interestingly, there
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was no discernible anatomical pattern between individual
Phospho1–/– animals, but regions lacking mineral exhibited
small focal areas of mineral nucleation at their borders, which
failed to propagate more widely.
In the very early studies of its function, characterization of
the Phospho1–/– bone phenotype was performed in young
juvenile mice, and therefore to examine the bone phenotype
more fully Javaheri and colleagues(31) investigated whether
PHOSPHO1 plays a persistent long‐term role in the adult bone’s
biology where skeletal turnover is relatively slow. Using digital
image correlation (DIC) the expected lower stiﬀness of
Phospho1–/– was found, which was corrected with age. µCT
analysis demonstrated several diﬀerences in tibial trabecular
microarchitecture, including trabecular number and connec-
tivity, between Phospho1–/– and wild‐type mice, which changed
transiently across four age groups, with signiﬁcant diﬀerences
detected in the 5‐week and 34‐week age groups, but not in the
7‐week or 16‐week groups. Upon examination of the cortical
bone, however, the authors noted a signiﬁcant reduction in
BV/TV in animals from 7 weeks of age that was not corrected
over time. NanoCT scanning (0.6‐µm resolution) furthermore
revealed a greater number of larger osteocyte lacunae, along
with higher vascular porosity in Phospho1–/– tibias, a surprising
ﬁnding which was compounded by an early increase in both
Pdpn (embryonic day 11 [E11]) mRNA expression in primary
osteoblast cell cultures, potentially indicating accelerated
terminal osteocyte diﬀerentiation in these cells.(31) PHOSPHO1
may therefore play a role in regulation of osteocytogenesis,
which in turn may regulate bone microarchitecture in skeletally
mature animals. Further research is required, however, to assess
whether this relationship is mediated through reduced miner-
alization, or whether PHOSPHO1 may act within a distinct
mechanism altogether. Our data also shows that the
Phospho1–/– phenotype is present during skeletal development,
with murine embryos exhibiting a reduced extent of miner-
alization across all bones during embryogenesis (unpublished
data; Fig. 2).
One‐year‐old Phospho1–/– mice showed reduced plasma con-
centrations of TNAP with a concomitant increase in ectonucleotide
pyrophosphatase/phosphodiesterase1 (NPP1), thereby resulting in
signiﬁcantly higher PPi concentrations compared with wild‐type
controls.(25) Intriguingly, high serum PPi is a key characteristic of
infantile hypophosphatasia in humans, with the resulting inhibition
of mineralization attributed to the ensuing rickets/osteoma-
lacia.(17,32) Yadav and colleagues(25) attempted to rescue the
Phospho1–/– phenotype by cross‐breeding with mice overexpres-
sing TNAP (ApoE‐Tnap) and thereby reduce PPi concentration.
Although the authors did indeed observe an approximately
fourfold increase in TNAP in plasma and a signiﬁcant reduction
in PPi, the hypomineralized Phospho1
–/– phenotype was not
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Fig. 1. (A) Goldner’s trichrome staining of wild‐type and Phospho1–/– tibial sections demonstrating osteoid accumulation in the trabeculae bone (red
staining; black arrowheads). Tibias were dissected from 21‐day‐old C67BL/6 mice and ﬁxed in 4% paraformaldehyde before decalciﬁcation in 10%
EDTA in PBS and standard histological processing. Three‐micrometer (3‐µm) sections were cut using a rotary microtome and used for staining. Scale
bars = 200 µm. (B) Radiographic images of 1‐year‐old Phospho1+/– and Phospho1–/– mice demonstrating thoracic scoliosis on ablation of Phospho1
(black arrowheads). Whole‐body images were acquired using a MX20 Specimen Radiograph System (Faxitron Bioptics, LLC, Tucson, AZ, USA). Scale
bars = 20 mm.
corrected, with animals exhibiting persistent skeletal defects at 7
months. Furthermore PHOSHO1; TNAP double knockout
(Phospho1–/–; Alpl–/–) mice exhibited complete ablation of skeletal
mineralization and perinatal lethality.(25) These data were aug-
mented and conﬁrmed in vitro with osteoblast‐like MC3T3‐E1 cell
lines (clones 14 and 24) along with ex vivo metatarsal cultures
using speciﬁc PHOSPHO1 and TNAP inhibitors in culture.(33)
PPi is known to regulate the expression of other mineraliza-
tion‐associated proteins, particularly osteopontin (OPN;
Spp1).(34–36) Along with PPi, OPN is another potent mineraliza-
tion inhibitor.(37–39) The protein’s inhibitory eﬀects are
mediated through its phosphorylation status,(40,41) and this
has been shown to be regulated by TNAP.(42) Signiﬁcantly
elevated OPN, which also exhibited a greater degree of
phosphorylation compared to controls, was found at the
protein and gene levels in serum and spinal lysates of
Phospho1–/– mice at 1 months and 3 months postnatally.(43)
Interestingly, no diﬀerences were observed in femoral lysates.
Yadav and colleagues(43) investigated the interplay between
PHOSPHO1 and OPN through the generation of Phospho1–/–;
Spp1–/– mice and found a partial rescue of the Phospho1–/–
phenotype, with animals at 1 month and 3 months of age
exhibiting a reduction in the typical hyperosteoidosis and
thoracic scoliosis that characterizes the single knockout animal.
The Phospho1–/– hypomineralized mouse phenotype is there-
fore partially attributable to an increased expression of OPN,
which may obstruct mineralization during bone formation. This
is likely exacerbated by a relative hyperphosphorylation of
OPN, mediated by the established reduced expression of Alpl in
Phospho1–/– mice.(25,43)
Collectively these ﬁndings establish a nonredundant role of
PHOSPHO1 in mediating biomineralization of the skeleton, as
well as its regulated synergy with TNAP, along with other
mineralization‐associated factors including PPi and OPN, as part
of this process.
Dental Mineralization
Along with its established role in bone biomineralization,
PHOSPHO1 has also been implicated in the mineralization process
of the dentition. McKee and colleagues(44) studied dentin
formation in perinatal mice and found localization of PHOSPHO1
to odontoblasts during the very ﬁrst steps of dentin formation.
Phospho1–/– mice exhibited reduced mineralization in the dentin
by histology, µCT, and radiography, a phenotype that was
aggravated by the additional deletion of one Alpl allele
(Phospho1–/–; Alpl+/–). Others have examined PHOSPHO1 function
in the other dental hard tissues, namely cementum and enamel.
PHOSPHO1 was found to show expression in osteoblasts and
cementoblasts of alveolar bone and cementum, respectively,
during their mineralization phases where osteoid accumulation
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Fig. 2. OPT reconstructions of mouse embryos at 17 days of gestation (E17) showing marked ablation of mineralization in bones of the skull in
Phospho1–/– animals. E17 C67BL/6 wild‐type and Phospho1–/– embryos were culled using Schedule 1 methods, ﬁxed in 4% paraformaldehyde and
whole‐mount stained in a 0.001% Alizarin Red solution in 1% potassium hydroxide. Samples were embedded in 1% agarose and scanned using a
Bioptonics 3001 OPT Scanner (Bioptonics, Medical Research Council Technology Group, UK). Data were reconstructed using NRecon (Bruker, Billerica,
MA, USA) and visualized using Imaris (Bitplane, Belfast, UK). Scale bars = 10 mm. OPT = optical projection tomography.
was evident in the bone and was accompanied by delayed
mineralization of the cellular cementum in Phospho1–/– animals.(45)
Intriguingly, acellular cementum formation was normal, despite
downregulation of Phospho1–/– in a bone sialoprotein knockout
model in this region.(46) PHOSPHO1 is therefore an enzyme critical
for the integrity of the periodontal tissue interface, along with
normal development of these hard tissues. In enamel, Phospho1–/–
mice exhibited a 25% increase in tissue volume, with a
signiﬁcantly reduced level of mineralization.(47) The authors
furthermore reported that ablation of PHOSPHO1 caused loss of
enamel prism morphology and an impaired crystal organization
compared to wild‐type mice.
At the level of local cellular regulation, control of miner-
alization through the PHOSPHO1 pathway has been shown to
be inﬂuenced by the TRPS1 transcription factor in an
odontoblast‐like cell line.(48) Mutations in the Trps1 gene are
associated with trichorhinophalangeal syndrome in humans
and manifest craniofacial and skeletal dysplasias associated
with defective endochondral mineralization.(49–51) Loss of
TRPS1 has also been implicated in abnormal tooth develop-
ment and mineralization.(52) Kuzynski and colleagues(48) over-
expressed Trps1 in preodontoblastic 17IIA11 cells and found
reduced mineralization compared with controls. Interestingly,
reduction of Trps1 expression also ablated mineralization and
was associated with downregulation of Phospho1 and Alpl
expression. The authors proposed that TRPS1 acts to repress
mineralization associated genes in dentin in a biphasic manner
to ﬁrst inhibit ectopic mineralization, and further to prevent
hypermineralization by modulation of osteogenic gene expres-
sion, including Phospho1.
The PHOSPHO1 Mineralization Mechanism:
Matrix Vesicle–Mediated Biomineralization
Matrix vesicles (MVs) are membrane‐bound nanospherical
bodies of approximately 100 to 300 nm in diameter that are
typically rich in lipids and proteins known to chelate Ca2+ and
Pi, and which are associated with both physiological and
pathological biomineralization.(53) Their function continues to
be remain controversial since their discovery in 1967 in growth
plate cartilage,(54,55) with some authors attributing these as
specimen‐preparation artifacts.(56) Nevertheless, many in vitro
and in vivo studies have shown the ﬁrst mineral crystals in
diverse mineralized tissues such as bone, dentin, cartilage, and
mineralized vasculature are associated with these structures in
the extracellular matrix (ECM).(55,57–63)
The structure and function of MVs in skeletal and vascular
mineralization has recently been reviewed by several
authors.(53,64–67) The biogenesis of these vesicles may occur
through multiple proposed mechanisms; however, the most
prevalent theories include polarized budding from the parental
cell membrane, or from microvilli on the cell surface, as
demonstrated in hypertrophic chondrocytes and SaOS‐2 osteo-
blast‐like cells.(68–71) The theorized function of MVs in biominer-
alization is to facilitate a localized concentration of Ca2+ and
Pi, protected from the ECM, from which hydroxyapatite or its
precursors may form.(53) Vesicles may also assist in concentrating
Pi to engender a Pi:PPi ratio that is permissible for mineraliza-
tion.(72) MVs are known to be enriched in Ca2+ by way of their
intracellular biogenesis from mitochondria under oxidative stress,
at least in growth‐plate chondrocytes.(73,74) Recently published
research by Chaudhary and colleagues(75) may correlate well with
these ﬁndings, showing that Pi stimulates release of MVs from
osteogenic cells, although the authors did not comment on their
mitochondrial origin.
Pi accumulation within MVs is thought to be mediated by
extravesicular and intravesicular phosphatases, of which
PHOSPHO1 plays a critical role.(11,20,25,26,76–78) Stewart and
colleagues(77) were the ﬁrst to suggest PHOSPHO1 as a major
intravesicular phosphatase, showing its presence in MVs
isolated from embryonic chick growth plates. This was more
recently conﬁrmed in MVs isolated from the ECM of both
cultured MC3T3 and SaOS‐2 osteoblast‐like cells using Western
blotting(75) and quantitative proteomics.(71,79) Further work
using both growth plate–derived and primary osteoblast–
derived vesicles established that although TNAP does indeed
liberate Pi extravesicularly, PHOSPHO1 is biochemically active
intravesicularly.(24,80) Therefore, it is hypothesized that accu-
mulation of Pi inside MVs occurs via a combination of the
intravesicular action of PHOSPHO1 and intravesicular traﬃcking
of TNAP‐generated Pi via a Type III Na‐Pi co‐transporter, PiT1
(encoded by the Slc20a1 gene in mice)(77,80) (Fig. 3A).
Experimental evidence for this hypothesis comes from the
work of Yadav and colleagues,(81) who generated a cartilage
speciﬁc PiT1 knockout mouse driven by a col2a1‐Cre on a
Phospho1‐null background (Phospho1–/–; PiT1
Col2/Col2). The
authors report an exacerbation of the Phospho1–/– phenotype,
including growth plate defects, extensive hyperosteoidosis,
decreased BMD, and impaired mechanical properties. MVs
isolated from diﬀerentiating chondrocytes in these animals
furthermore demonstrated a loss of their capacity to nucleate
hydroxyapatite crystals compared to both Phospho1–/– and
wild‐type controls.(81) Interestingly, both Phospho1–/– and
Phospho1–/–; PiT1
Col2/Col2 MV were reduced in numbers com-
pared to wild‐types, potentially indicating a role for PHOSPHO1
in MV biogenesis. Together, these studies, along with those
characterizing the Alpl–/– and Phospho1–/–; Alpl–/–
mice,(16,17,20,21,25) aﬀord good evidence for this mechanism
integrating the PHOSPHO1 and TNAP Pi generation pathways.
Although this work provides a strong evidence base for the
pivotal role of PHOSPHO1 in vesicle‐mediated biomineralization,
the speciﬁc biochemical pathway within it by which it achieves
intravesicular Pi liberation remains unclear. Stewart and collea-
gues(82) proposed a mechanism through which PHOSPHO1’s
substrates PEA and PCho may be generated intravesicularly by
enzymatic action upon the vesicle’s phospholipid membrane, as
mediated by a phospholipase A2 (PLA2) and ectonucleotide
pyrophosphatase/phosphodiesterase 6 (NPP6)(82) (Fig. 3B). The
PLA2 family of enzymes catalyze cleavage of the acyl group at the
sn‐2 acyl position of glycerophospholipids resulting in a free fatty
acid and lysophospholipid (LPL).(83–85) These enzymes may
therefore act to breakdown phosphatidylcholine (PC) and
phosphatidylethanolamine (PE) in the MV membrane, forming
lysophosphatidylethanolamine and lysophosphocholine LPLs,
respectively, along with arachidonic acid.(82) Indeed, the MV
membrane has been shown to be enriched in phospholipids
containing PCho and PEA, which progressively decline during
mineralization,(74,86,87) whereas PCho was also identiﬁed as an
abundant metabolite in developing mouse long bones by matrix‐
assisted laser desorption/ionization‐imaging mass spectro-
metry.(88) There are upward of 30 identiﬁed mammalian PLA2
enzymes that exhibit a huge range of localizations (including
secreted, cytosolic, and lysosomal groups) and have been shown
to be involved with many physiological and pathological
processes.(83–85) Mebarek and colleagues(89) comprehensively
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reviewed the evidence for the role of phospholipases in
mineralization, noting several experimental studies conﬁrming
expression of both secreted and cytosolic PLA2s in chondrocytes
and osteoblasts where they play several roles. Although some
speciﬁc PLA2s have been shown to have an eﬀect on bone
formation,(90) it is currently unclear whether these act directly
within the mineralization process. Therefore, further research is
required to identify speciﬁc candidate proteins that fulﬁll this
niche.
A second enzymatic processing phase is hypothesized to
convert generated LPL to PCho for direct hydrolysis by
PHOSPHO1, mediated by NPP6.(82) NPP6 is a member of the
nucleotide pyrophosphatase/phosphodiesterase family and has
been shown to possess lysophospholipase C activity, catalyzing
the conversion of lysophosphocholine with a monoacylglycerol
by‐product.(91–93) Expression of NPP6 has been demonstrated
in bone tissue lysate and was immunolocalized to hypertrophic
chondrocytes and forming bone surfaces.(82) Speciﬁc localiza-
tion of NPP6 to MVs has yet to be established, however.
Alternative biochemical pathways through which PHOSPHO1
substrates may be generated have also been proposed (Fig. 3C).
Neutral sphingomyelinase 2 (nSmase2) is encoded by the Smpd3
gene in mice and is capable of catalyzing the hydrolysis of
another MV membrane phospholipid, sphingomyelin, to pro-
duce PCho with a ceramide byproduct.(94) The fro mutation in
the Smpd3 gene generates a distinctive phenotype with
extensive musculoskeletal defects resulting in dwarﬁsm.(95,96)
Khavandgar and colleagues(97) demonstrated that the fro/fro
mouse exhibits delayed mineralization of the long bones and
calvaria, along with impaired hypertrophy in growth plate
chondrocytes during embryonic development. Using tissue‐
speciﬁc mouse knockout models it was also established that
Smpd3 expression is required in both osteoblasts and chon-
drocytes in a cell‐autonomous manner for normal bone
development.(97,98) These eﬀects were moreover shown to
inﬂuence mineralization during tooth development and fracture
healing.(99,100) Like PC and PE, sphingomyelin is enriched in MV
preparations and declines during mineralization,(74,86,87) whereas
the nSmase2 enzyme has been localized to MV isolates in
conjunction with PHOSPHO1.(79) nSmase2‐mediated production
of PCho may therefore provide another pathway for the
intravesicular generation of PHOSPHO1 substrates. Another
potential alternative pathway includes generation of PCho by
phosphorylation of choline through the action of the α and β
choline kinases (encoded by the Chkα and Chkβ genes,
respectively). Although mice lacking Chkα display lethality
during embryonic development,(101) the Chkβ–/– mouse exhibits
forelimb deformities and delayed mineralization, accompanied
by an extended and disorganized hypertrophic zone within the
growth plates at the distal radius and ulna.(102) PCho was also
shown to be reduced by ∼75% in primary chondrocytes isolated
from these animals.(102) Intriguingly, PHOSPHO1 was upregu-
lated in Chkβ–/– primary chondrocytes, potentially indicating
compensation for a restricted substrate availability.(102) Both
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Fig. 3. Schematic diagram illustrating the hypothesized mechanism of PHOSPHO1 function within MVs. (A) PHOSPHO1 functions synergistically with
TNAP: (1) TNAP hydrolyses its substrates to produce Pi extravesicularly; (2) extravesicular Pi is transported into the MV via PiT1; (3) PHOSPHO1
hydrolyses Pcho intravesicularly to further accumulate Pi. (B) Generation of PHOSPHO1 substrates within MVs: (1) an unidentiﬁed PLA2 converts PC
from the vesicle membrane to lysoPC; (2) NPP6 subsequently catalyses the hydrolysis of lysoPC to generate Pcho; (3) PHOSPHO1 liberates Pi from
PCho. (C) Alternative pathways of PCho generation: (1) nSmase2 breaks down SM from the MV membrane to form Pcho; (2) the α/β choline kinases
phosphorylate choline to form PCho; (3) PHOSPHO1 generates Pi from PCho.
Chkα and Chkβ were found to be expressed in human
osteoblast‐like MG‐63 cells, and gene silencing of Chkα resulted
in a reduction of ∼70% in cellular PCho with an accompanied
inhibition of TNAP activity and mineralization in culture.(103)
Endocrinology and Regulation
As a critical eﬀector of biomineralization it is likely that
PHOSPHO1 expression and function will be stringently
controlled at both the local and systemic level. As a major
organ, and one which is metabolically expensive to produce
and maintain, it is well established that bone formation and
resorption are tightly controlled by many factors during
development and in adulthood, some of the most signiﬁcant
of which include the sex steroids,(104–106) vitamin D,(107–109) and
parathyroid hormone (PTH).(110–112) Whether the observed
diﬀerences in mineralization caused by regulatory inﬂuences
are caused wholly or partly by control of PHOSPHO1 or other
associated proteins is as yet unknown.
Some evidence for the systemic regulation of PHOSPHO1
comes from work surrounding the eﬀect of PTH on osteoblasts,
with RNA‐seq in an osteocyte‐like cell line (IDG‐SW3 cells)
stimulated with PTH in culture demonstrated an eﬀect on both
Phospho1 and Smpd3 expression.(113) Houston and collea-
gues(114) extended these analyses, examining the expression
of Phospho1, Smpd3, and Alpl speciﬁcally in MC3T3 osteoblast‐
like cells and ex vivo calvaria culture models with continuous
PTH exposure. The authors report rapid and coordinate
downregulation of Phospho1 and Smpd3 expression after the
addition of PTH to culture media, which was likely regulated
through the cAMP/PKA signaling pathway. This downregula-
tion of both Phospho1 and Smpd3 was independently found in
Kusa 4b10 cells and in young rats exposed to PTH and PTH‐
related protein 1 (PTHrP).(115,116) The catabolic eﬀects of
continuous PTH on the skeleton are well demonstrated in
human conditions such as hyperparathyroidism; however,
much research has associated this with the upregulation of
osteoclastogenesis through the RANKL/OPG axis.(117–119) These
data may indicate, however, a simultaneous mechanism
eﬀecting inhibition of bone formation as mediated by
PHOSPHO1. The transcription and posttranslational modiﬁca-
tion (phosphorylation) of Runx2, the transcription factor and
master regulator of osteoblast diﬀerentiation, is also strongly
enhanced by PTH.(120) Interestingly, the overexpression of
Runx2 in mouse limb bud cultures simultaneously enhances the
expression of both Phospho1 and Smpd3.(121)
Collectively, these data surrounding PTH tentatively suggest
that control of bone biomineralization may occur by mod-
ulating PHOSPHO1 expression, and thereby the MV‐mediated
biomineralization mechanism. This relationship is, however,
currently far from explicit and much further research is required
to establish the regulatory mechanisms behind PHOSPHO1
expression and function within the context of the MV.
PHOSPHO1 in Pathologies of Mineralization
Aside from its central function in mediating physiological
biomineralization, PHOSPHO1 may also have a role to play in
the onset of pathological mineral formation; for example in
vascular calciﬁcation. Phospho1 is upregulated during miner-
alization of vascular smooth muscle cells (VMSCs) in culture,
whereas Phospho1–/– VSMCs exhibited a signiﬁcant reduction
in mineral generation.(122) Also, the PHOSPHO1 inhibitor, MLS‐
0263839 reduced calciﬁcation of cultured VSMCs by ∼60% and
when combined with the TNAP inhibitor MLS‐0038949, calciﬁca-
tion of VSMCs was reduced by ∼80%.(122) Phospho1 is also
upregulated during atherosclerotic vascular calciﬁcation in a
rabbit model.(123) Furthermore, Hortells and colleagues(124)
induced aortic calciﬁcation in a rat nephrectomy model with a
1.2% phosphorous diet for 12 weeks postsurgery and observed
signiﬁcant upregulation of Phospho1 expression in animals
exhibiting calciﬁcation, along with several other mineralization‐
associated genes. These studies suggest that PHOSPHO1 has a
critical role in VSMC mineralization and that “phosphatase
inhibition” may oﬀer therapeutic strategies to mitigate vascular
calciﬁcation.
Several authors have investigated the process responsible for
vascular calciﬁcation, with some implicating PHOSPHO1 and
TNAP as part of the MV mechanism.(125,126) Scanning electron
microscopy (SEM) and focused ion beam scanning electron
microscopy (FIB‐SEM) of human calciﬁed valves and vasculature
revealed nanospherical particles composed of crystalline
calcium phosphate.(127) Using in vitro models together with
calciﬁed human tissue, these particles were later implicated in
the formation of mineralized atherosclerotic plaques through
their initial aggregation and nucleation of the mineral
phase.(128) Furthermore, particles isolated from mineralized
aortas were subsequently shown to induce pathological
changes in valvular endothelial cells (VECs) and valvular
interstitial cells (VICs) in culture.(129) These studies demonstrate
compelling similarities between calciﬁed particles found in the
vasculature and MVs. The localization of PHOSPHO1 or other
MV‐associated enzymes with these structures has not as yet,
however, been conﬁrmed and so the mechanism behind their
generation remains elusive.
There is now substantial evidence that the mineralization
status of the subchondral bone is altered in osteoarthritis, and
that this may lead to modiﬁed mechanical integrity, engen-
dering greater articular cartilage degeneration.(130) Phospho1 is
upregulated during chondrocyte diﬀerentiation,(131) and aged
hypomineralized Phospho1–/– mice exhibit increased articular
cartilage degradation and osteophyte formation, when com-
pared to the age‐matched wild‐type mice.(132) Further, non-
invasive loading of Phospho1–/– mouse knee joints revealed
diminished loading‐induced changes in the subchondral bone
plate thickness and epiphyseal trabecular bone microarchitec-
ture.(132) Together, these data suggest that the hypominer-
alized bone phenotype in Phospho1–/– mice provokes osteoar-
thritis pathology. This therefore implies that local modiﬁcations
in the bone matrix mineralization may underpin subchondral
bone sclerosis in osteoarthritis; however, further analyses are
required to fully deﬁne this relationship.
There are also more speculative roles for PHOSPHO1 in
osteoarthritis because of its role as a phosphatase capable of
hydrolyzing PCho and PEA. Lipidomic analysis of the synovial
ﬂuid from patients with osteoarthritis suggests that alterations
in the phospholipid composition and concentrations are
associated with disease development, due to the lubricating
function of the synovial ﬂuid in the joint.(133) Speciﬁcally, PC
concentrations are increased in the synovial ﬂuid of both early
(2.7‐fold) and late (5.4‐fold) osteoarthritic patients in compar-
ison to controls.(133) Similarly, there has been reported high
activity of PLA2, thought to break down PC, in the synovial ﬂuid
of osteoarthritic patients(134) and a role for PLA2, in articular
cartilage chondrocyte function.(135) It has been suggested that
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the ratio of PC to lysophosphatidylcholine is a good diagnostic
marker for rheumatoid arthritis.(136) However, whether this is
the case for osteoarthritis and the potential involvement of
PHOSPHO1 in this is yet to be established.
Other Physiological Roles
In the 20 years since its characterization, the vast majority of
research focusing on PHOSPHO1 has concentrated on biominer-
alization. However, as a phosphatase capable of hydrolyzing PCho
and PEA with the generation of metabolites such as choline,
PHOSPHO1 has the potential for activity in many other body
systems. PC and PE are two of the most abundant lipids in the
body, comprising 40% to 50% and 15% to 20%, respectively, of
total cellular phospholipids of any given tissue in mammals.(137)
These molecules are therefore of critical importance in a huge
variety of biological systems, from the integrity of plasma
membranes, and other structures such as vesicles, lipoproteins
and chylomicrons, to regulating the activity of proteins at the cell
membrane.(137,138) Interestingly, the breakdown products from PC
in particular have also been implicated as signaling mole-
cules.(139,140) Although speculative, it is therefore an intriguing
possibility that PHOSPHO1 may have a role to play in the
biosynthesis and catalysis pathways of these phospholipids,
regulating substrate availability. Choline is the breakdown product
from PHOSPHO1 activity on the LPL lysophosphatidylcholine
derived from PC, and is an essential dietary nutrient in mammals.
Although choline is primarily used in PC biosynthesis, it may also be
used to generate betaine in the liver and kidney, or acetylated to
form the neurotransmitter acetylcholine in the brain.(141)
PHOSPHO1 may therefore be an appealing candidate to act within
a secondary mechanism of choline homeostasis in these and other
tissues. Indeed, gut enteroids maintained in choline‐deﬁcient media
exhibited hypomethylation at 3′ CpG islands within the Phospho1
gene, potentially regulating gene expression.(142)
One system within which PHOSPHO1 plays a signiﬁcant role in
this regard is erythropoiesis. An expression quantitative trait locus
(eQTL) analysis initially found that single‐nucleotide polymorph-
isms (SNPs) associated with β‐thalassemia in human peripheral
blood samples were also associated with changes in PHOSPHO1
expression.(143) PHOSPHO1 was also found to be substantially
enriched in erythroblasts undergoing diﬀerentiation.(144) Subse-
quently Huang and colleagues(145) investigated PHOSPHO1 in
terminal erythropoiesis; a process during which the phospholipid
composition of red cells is substantially altered. PHOSPHO1
expression was signiﬁcantly upregulated during erythroblast
diﬀerentiation, and moreover loss of PHOSPHO1 induced
defective erythropoiesis accompanied by a lack of choline
generation and an increased phosphocholine:choline ratio.
Several other studies have found intriguing associations
between PHOSPHO1 expression and disorders of altered energy
metabolism such as diabetes and obesity. Epigenome‐wide
association studies (EWAS) have found signiﬁcant associations
between methylation at loci within the PHOSPHO1 and the future
risk of type‐2 diabetes in human cohorts.(146,147) Indeed, Willmer
and colleagues(148) highlighted diﬀerential methylation at sites
within the PHOSPHO1 gene as a potentially useful biomarker for
clinical application in the early detection of type‐2 diabetes.
Moreover, increased methylation was positively correlated with
high density lipoprotein (HDL) concentration in blood and was
decreased in muscle tissue from diabetic patients.(147) This
relationship with HDL concentration was also reproduced
independently in an EWAS focused on serum lipid proﬁles
conducted in a separate cohort.(149) Relatedly, Wu and collea-
gues(150) further found an association between PHOSPHO1 and
SNPs relating to clinical measures of obesity in a Chinese
population. These studies provide a promising avenue of
investigation for future research to consider the mechanisms
through which PHOSPHO1 may act to inﬂuence lipid metabolism
and disorders of its dysregulation such as diabetes and obesity.
Supporting this idea, changes in Phospho1 expression have been
found in several studies examining the thermogenic brown
adipose tissue (BAT) and the browning of white adipose tissue
(WAT), of great relevance to obesity. Phospho1 is expressed at a
higher level in BAT than WAT,(151) and suppression of fatty acid
oxidation in adipose tissues causes a downregulation in expression
during cold challenge.(152) Furthermore, studies that have investi-
gated creatine metabolism as an alternative pathway for thermo-
genesis in beige fat have implicated PHOSPHO1 in this process,
although the speciﬁc mechanism remains elusive.(153,154)
Inhibition of PHOSPHO1—a Therapeutic Target?
The LOPAC and Spectrum chemical reference libraries were used
to identify potential chemical inhibitors of PHOSPHO1 and
semiautomated high‐throughput chemical screening used to
test inhibition of PEA hydrolysis.(24) Of those identiﬁed, three
molecules, Lansoprazole, Ebseleln, and SCH202676, exhibited
noncompetitive inhibition of recombinant PHOSPHO1 activity by
80% or more.(24) This study showed that neither Lansoprazole
nor SCH202676 inhibited TNAP activity, but Lansoprazole has
recently been shown to act as a noncompetitive inhibitor of
TNAP.(155) Following this, Bravo and colleagues(156) synthesized a
series of benzoisothiazolone inhibitors of PHOSPHO1; the ﬁnal
selection from these inhibitors was tested and passed medicinal
chemistry criteria in deliverability, metabolic stability, solubility,
and permeability, while also demonstrating no cellular toxicity.
The development of these compounds opens the potential
for inhibition of PHOSPHO1 activity as a therapeutic interven-
tion. Although there has been no experimental research
exploring this possibility to date, the imputation of PHOS-
PHO1’s association with pathologies in both biomineralization
and lipid metabolism may make it an attractive drug target in
the future. In terms of disorders of pathological mineralization,
although the PHOSPHO1‐mediated mineralization mechanism
is critical for the proper development of the skeleton in
immature organisms, as has been discussed here, there is
currently no evidence to suggest that it plays an active role in
maintenance of the skeleton in adulthood. Ablation of
mineralization in the adult may be desirable when attempting
to control soft tissue mineralization, eg, vascular calciﬁcation
and also ectopic bone formation, as is the case in several
musculoskeletal disorders including osteoarthritis. In these
instances pharmacological inhibition of PHOSPHO1 may prove
to represent an eﬀective intervention that also entails limited
adverse oﬀ‐target eﬀects.
Outlook
Over the past 20 years PHOSPHO1 has been an increasing focus
of research in the bone biology and biomineralization
communities. Work performed in our and in other groups has
succeeded in establishing its canonical role in MV‐mediated
biomineralization of the skeleton and dentition, while opening
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new ﬁelds of investigation into its function in other body
systems. Many questions remain to be answered surrounding
aspects of PHOSPHO1’s biology, including detailed elucidation
of its upstream biochemical mechanism, targeting of the
enzyme to MVs, how local and systemic regulation is integrated
with other aspects of bone biology during the bone formation
process, and the precise role of PHOSPHO1in musculoskeletal
disease. Future studies integrating aspects of structural biology
and biomineralization with cellular and molecular biology and
endocrinology will give us a holistic appreciation of these
processes and contribute to our understanding in this
fundamental aspect of bone biology.
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